WGO Graded Evidence: Osteoporosis

Level: Clinical Trials: 21 Abstracts

Legend:   : Special Mention  : Important  : Very Important  : Key Development
	A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. S Henderson, N Hoffman, R Prince, Am J Gastroenterol. 2006 Jan:119-23
	Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. RH Boone, AM Cheung, LM Girlan, EJ Heathcote, Dig Dis Sci. 2006 Jun:1103-12
	Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. F Walther, C Fusch, M Radke, S Beckert, A Findeisen, J Pediatr Gastroenterol Nutr. 2006 Jul:42-51
	Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis. H Rautiainen, M Færkkilæ, M Neuvonen, T Sane, AL Karvonen, H Nurmi, P Kærkkæinen, PJ Neuvonen, JT Backman, Aliment Pharmacol Ther. 2006 Dec:1545-52
Supplementary evidence:
	A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. KM Wissing, N Broeders, R Moreno-Reyes, C Gervy, B Stallenberg, D Abramowicz, Transplantation. 2005 Jan 15:108-15
	Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. N Guañabens, A Parés, I Ros, L Alvarez, F Pons, L Caballería, A Monegal, MJ Martínez de Osaba, M Roca, P Peris, J Rodés, Am J Gastroenterol. 2003 Oct:2268-74
	Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. CH Chesnut III, A Skag, C Christiansen, R Recker, JA Stakkestad, A Hoiseth, D Felsenberg, H Huss, J Gilbride, RC Schimmer, PD Delmas, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE), J Bone Miner Res. 2004 Aug:1241-9
	Efficacy and safety of ibandronate given by intravenous injection once every 3 months. S Adami, D Felsenberg, C Christiansen, J Robinson, RS Lorenc, P Mahoney, K Coutant, RC Schimmer, PD Delmas, Bone. 2004 May:881-9
	Evaluation of three population-based strategies for fracture prevention: results of the osteoporosis population-based risk assessment (OPRA) trial. AZ Lacroix, DS Buist, SK Brenneman, TA Abbott 3rd, Med Care. 2005 Mar:293-302
	Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. R Recker, JA Stakkestad, CH Chesnut 3rd, C Christiansen, A Skag, A Hoiseth, M Ettinger, P Mahoney, RC Schimmer, PD Delmas, Bone. 2004 May:890-9
	Interventions to improve osteoporosis treatment following hip fracture. A prospective, randomized trial. MJ Gardner, RH Brophy, D Demetrakopoulos, J Koob, R Hong, A Rana, JT Lin, JM Lane, J Bone Joint Surg Am. 2005 Jan:3-7
	Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. V Abitbol, JY Mary, C Roux, JC Soulé, J Belaiche, JL Dupas, JP Gendre, E Lerebours, S Chaussade, Groupe D'etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID), Aliment Pharmacol Ther. 2002 May:919-27
	Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. D Kendler, AW Kung, Gel-H Fuleihan, JG González González, KA Gaines, N Verbruggen, ME Melton, Maturitas. 2004 Jul 15:243-51
	Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. S Nishiguchi, S Shimoi, H Kurooka, A Tamori, D Habu, T Takeda, S Kubo, J Hepatol. 2001 Oct:543-5
	Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. E Barrett-Connor, JA Cauley, PM Kulkarni, A Sashegyi, DA Cox, MJ Geiger, J Bone Miner Res. 2004 Aug:1270-5
	Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. C Meier, HW Woitge, K Witte, B Lemmer, MJ Seibel, J Bone Miner Res. 2004 Aug:1221-30
	Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid. [No Authors Listed], Prescrire Int. 2005 Feb:5-9
	The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women. S Arrenbrecht, P Caubel, P Garnero, D Felsenberg, Maturitas. 2004 Jul 15:197-207
	Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. C von Tirpitz, J Klaus, M Steinkamp, LC Hofbauer, W Kratzer, R Mason, BO Boehm, G Adler, M Reinshagen, Aliment Pharmacol Ther. 2003 Mar 15:807-16
	Wheat bran fiber supplementation and bone loss among older people. Z Chen, WA Stini, JR Marshall, ME Martínez, JM Guillén-Rodríguez, D Roe, DS Alberts, Nutrition. 2004 Sep:747-51
	YOUTH: decisions and challenges in designing an osteoporosis prevention intervention for teen girls. LL DeBar, C Ritenbaugh, N Vuckovic, VJ Stevens, M Aickin, D Elliot, E Moe, E Orwoll, D Ernst, LM Irving, Prev Med. 2004 Nov:1047-55